论文部分内容阅读
目的分析研究伊可尔治疗病毒疣的临床疗效。方法回顾性分析2012年1月-12月期间在我院治疗的56例病毒疣患者的临床资料。将56例患者随机分为治疗组和对照组各28例,治疗组给予伊可尔治疗,对照组给予左旋咪唑治疗,观察记录两组临床疗效及不良反应。结果治疗组总有效率为92.86%,对照组总有效率为75.00%,治疗组临床疗效明显高于对照组,两组比较差异有统计学意义(P<0.05)。两组患者均无严重不良反应发生。结论伊可尔治疗病毒疣疗效显著,安全性好,可进一步推广使用。
Objective To analyze the clinical efficacy of Irglivol in the treatment of viral warts. Methods The clinical data of 56 cases of viral warts treated in our hospital from January to December in 2012 were analyzed retrospectively. Fifty-six patients were randomly divided into treatment group and control group, with 28 cases in each group. The treatment group was given Igolizarin and the control group was given levamisole. The clinical efficacy and adverse reactions were observed and recorded in both groups. Results The total effective rate was 92.86% in the treatment group and 75.00% in the control group. The clinical curative effect in the treatment group was significantly higher than that in the control group. There was significant difference between the two groups (P <0.05). No serious adverse reactions occurred in both groups. ConclusionIrkel treatment of viral warts significant effect, good safety, can be further promoted.